Detalles de la búsqueda
1.
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.
Clin Exp Immunol
; 210(2): 91-103, 2022 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36208448
2.
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies.
Front Immunol
; 13: 1110388, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36605207
3.
Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies.
Front Immunol
; 12: 707463, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34305948
4.
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Front Immunol
; 10: 40, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30778345
Resultados
1 -
4
de 4
1
Próxima >
>>